Work

#1705024 A Randomized Phase 3 Trial to Assess Efficacy and Safety of a Novel Formulation of Octreotide Subcutaneous Depot (CAM2029) in Patients With Acromegaly

Year: 2024

Type: article

Source: Endocrine Practice

DOI: 10.1016/j.eprac.2024.03.359

Authors: Julie Silverstein, Julie Silverstein, Diego Ferone, Pamela Freda, Laurence Katznelson, Federico Gatto, Pinar Kadioglu, Pietro Maffei, Jochen Seufert, Joanna L. Spencer-Segal, Elena Isaeva, Alexander Dreval, Maria Harrie, Agneta Svedberg, Fredrik Tiberg

Institutions: Washington University in St. Louis, Ospedale Policlinico San Martino, Columbia University, Stanford University, Istanbul University-Cerrahpaşa, Istanbul University, Azienda Ospedale - Università Padova, University of Freiburg, University of Michigan, State Autonomous Institution of Health Interregional Clinical Diagnostic Center, Camurus AB (Sweden)

Language: English

Topic: Pituitary Gland Disorders and Treatments

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4396740279

FWCI:

Cites:

Cited by:

Related to: 10